(Q24245627)

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

The use of budesonide in the treatment of active Crohn's disease is good clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

Steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

Maintenance therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

Budesonide: is no evidence of a difference the same as evidence of no difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

Budesonide in the management of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

Budesonide for maintenance of remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Conventional treatment of Crohn's disease: objectives and outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

[Clinical effects of 5-aminosalicylic acid preparations in Crohn disease]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

[Consequences of galenic differences and outcome of clinical trials with budesonide and 5-aminosalicylic acids for therapy of Crohn disease]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

[Topical steroids in chronic inflammatory bowel diseases]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Magnetic resonance imaging of Crohn disease: early recognition of treatment response and relapse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Effect of cortisol and ACTH on corticosteroid-suppressed peripheral blood natural killer cells from healthy volunteers and patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

A comparison of budesonide and mesalamine for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Adjuvant post-operative therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide in the treatment of Crohn's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Treatment of joint pain in Crohn's patients with budesonide controlled ileal release

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

[Pyostomatitis vegetans and Crohn's disease. A specific association of 2 diseases]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide for inflammatory bowel disease. Is it a magic bullet?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Treatment of Crohn's disease at the turn of the century.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Oral budesonide approved for active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Severe hypokalemia after budesonide treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide: not for the long haul

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Oral budesonide in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Increased levels of homocysteine in patients with Crohn's disease are related to folate levels.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

A successful switch from prednisone to budesonide for neuropsychiatric adverse effects in a patient with ileal Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Treatment of Crohn's disease with budesonide: this rose still has thorns!

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Controlled-release budesonide in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021

Budesonide or Prednisolone in Active Crohn's Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000296.PUB2

7 January 2021